<DOC>
	<DOCNO>NCT01793441</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , parallel group , placebo-controlled , proof concept study investigate efficacy safety RG7314 adult participant ASD . In Stage I study , participant randomize 2:1 receive daily oral dos 1.5 milligram ( mg ) RG7314 placebo 12 week . After independent safety review , study may proceed Stage II . In Stage II study , additional participant randomize 2:1 receive daily oral dos 4 mg RG7314 placebo 12 week . After independent safety review , Stage III start wherein additional participant randomize 2:1 receive daily oral dos 10 mg RG7314 placebo 12 week . During Stage III , safety review independent safety review twice safety signal observe , additional participant randomize 1:1:1 either receive 1.5 milligram per day ( mg/day ) 10 mg/day RG7314 orally placebo 12 week Stage IV .</brief_summary>
	<brief_title>A Study RG7314 Investigate Efficacy Safety Individuals With Autism Spectrum Disorders ( ASD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Participants meet Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criteria ASD Tenth Revision International Classification Diseases Related Health Problems ( ICD10 ) criteria Autism diagnosis SRS2 ( Tscore ) great equal ( &gt; /= ) 66 CGIS &gt; /=4 ( moderately ill ) Participants Intelligence Quotient ( IQ ) &gt; /=70 ( Wechsler Abbreviated State Intelligence ) A body mass index ( BMI ) 18 40 kilogram per square meter ( kg/m^2 ) inclusive Language , hear vision compatible study measurement judge investigator Lives ( substantial period contact ) caregiver willing able attend visit require , oversee participant 's compliance protocolspecified procedure study medication dosing , report participant 's status via completion study assessment . Any period absence must cover another caregiver . Noncohabitating caregiver ( ) must spend sufficient time participant , opinion investigator , caregiver ( ) reliably assess participant 's mental status , activity behavior . Alcohol and/or substance abuse/dependence last 12 month A significant risk suicidal behavior , opinion investigator Systolic blood pressure great ( &gt; ) 140 less ( &lt; ) 90 millimeter mercury ( mm Hg ) , diastolic blood pressure &gt; 90 less ( &lt; ) 50 mm Hg Resting pulse rate &gt; 90 &lt; 40 beat per minute Use prohibit medication herbal remedy within 2 week prior randomization , 5 halflives ( whichever longer ) Initiation new major change psychological intervention within 4 week prior randomization . Minor change ongoing treatment consider significant Participation investigational drug device study within 60 day prior randomization</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>